Association of research and development investments with treatment costs for new drugs approved from 2009 to 2018

OJ Wouters, LA Berenbrok, M He, Y Li… - JAMA network …, 2022 - jamanetwork.com
Importance Drug companies frequently claim that high prices are needed to recoup
spending on research and development. If high research and development costs justified …

Patent term restoration for top-selling drugs in the United States

RF Beall, JJ Darrow, AS Kesselheim - Drug Discovery Today, 2019 - Elsevier
Highlights•Most new drugs receive a patent term restoration (PTR) extension.•Patents with
PTR commonly expire more than 12 years after marketing approval.•Patents with PTR …

The characteristics of patents impacting availability of biosimilars

VL Van de Wiele, RF Beall, AS Kesselheim… - Nature …, 2022 - nature.com
The characteristics of patents impacting availability of biosimilars | Nature Biotechnology
Skip to main content Thank you for visiting nature.com. You are using a browser version …

Market exclusivity length for drugs with new generic or biosimilar competition, 2012–2018

BN Rome, CWC Lee… - Clinical Pharmacology & …, 2021 - Wiley Online Library
Brand‐name drugs have periods of market exclusivity before generic competition begins.
Due to high brand‐name drug prices charged during this period, market exclusivity is an …

Analysis of patent and regulatory exclusivity for novel agents in China and the United States: a cohort study of drugs approved between 2018 and 2021

X Luo, L Yang, X Du, J Yang, F Qian… - Clinical Pharmacology …, 2022 - Wiley Online Library
Patent and regulatory exclusivity shall constitute incentives for pharmaceutical companies to
develop new drugs. This study aims to investigate the differences in the patent term …

Pre-market development times for biologic versus small-molecule drugs

RF Beall, TJ Hwang, AS Kesselheim - Nature Biotechnology, 2019 - nature.com
3. Regalado, A. More than 26 million people have taken an at-home ancestry test. MIT
Technology Review https://www. technologyreview. com/s/612880/more-than-26-million …

The prevalence of drug patent term extensions in the United States, 2000–2018

VL Van de Wiele, AS Kesselheim, S Nagar… - Nature …, 2023 - nature.com
The prevalence of drug patent term extensions in the United States, 2000–2018 | Nature
Biotechnology Skip to main content Thank you for visiting nature.com. You are using a browser …

[HTML][HTML] Reimagining pharmaceutical market exclusivities: should the duration of guaranteed monopoly periods be value based?

RF Beall, A Hollis, AS Kesselheim, E Spackman - Value in Health, 2021 - Elsevier
Objectives To describe the main features of a pharmaceutical market in which the duration of
guaranteed monopoly periods would correspond to a new pharmaceutical product's value …

Authorized generics vs. branded generics: a perspective

B Latwal, A Chandra - Journal of Generic Medicines, 2021 - journals.sagepub.com
Nowadays, there are many generic medications available in the market. Their sale is
increasing day by day due to their lower cost and affordability by most of the customers …

US spending associated with transition from daily to 3-times-weekly glatiramer acetate

BN Rome, FA Tessema… - JAMA internal medicine, 2020 - jamanetwork.com
Importance Market exclusivity for daily injections of glatiramer acetate, a disease-modifying
therapy for multiple sclerosis, expired in 2015. In 2014, the manufacturer launched an …